Gal-3 Cancer Research Results

Gal-3, LGALS3, galectin-3: Click to Expand ⟱
Source:
Type:

LGALS3 (Galectin-3; Gal-3) — Beta-galactoside-binding lectin expressed intracellularly, extracellularly, and on the cell surface. Galectin-3 regulates cell adhesion, proliferation, migration, apoptosis, inflammation, fibrosis, angiogenesis, innate and adaptive immune responses, and tumor progression.

Typical modulation in cancer: Frequently ↑ and generally tumor-promoting. Elevated Galectin-3 can enhance proliferation, survival, migration, invasion, angiogenesis, metastasis, immune evasion, and resistance to chemotherapy. Cytoplasmic Galectin-3 can suppress mitochondrial apoptosis and interact with signaling proteins including RAS, BCL2, and MYC. However, biological effects can vary according to cancer type and subcellular localization.

Typical modulation in Alzheimer’s disease: ↑ Galectin-3 is generally associated with microglial activation, neuroinflammation, amyloid-beta pathology, and cognitive impairment. Galectin-3 is enriched in plaque-associated microglia, can interact with TREM2, and may amplify inflammatory responses. Galectin-3 inhibition or deficiency has reduced inflammatory activation and amyloid pathology in experimental AD models.

Typical mechanistic relationships: Galectin-3 ↑ → microglial activation ↑; TREM2 signaling modulation; TLR4-related inflammatory signaling ↑; cytokine release ↑; Aβ-associated neuroinflammation ↑. In cancer, Galectin-3 ↑ can also promote RAS signaling, BCL2-associated survival, angiogenesis, invasion, and chemoresistance.
Scientific Papers found: Click to Expand⟱
8825- MCP,    modified citrus pectin supplement
- Review, Var, NA
Gal-3↓, *antiOx↑, Imm↑, IronCh↑, TumMeta↓, TumCP↓, PSA↓, NK cell↑, T-Cell↑,
8815- MCP,    Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension
- Trial, Nor, NA
Dose↝, Gal-3↓,
8816- MCP,    Modified citrus pectin inhibits breast cancer development in mice by targeting tumor-associated macrophage survival and polarization in hypoxic microenvironment
- vitro+vivo, BC, MDA-MB-231 - in-vitro, BC, 4T1
GlucoseCon↓, GLUT1↓, Gal-3↓, ROS↓, NRF2↓, Hif1a↓, angioG↓, pol-M2 MC↓, p‑STAT3↓, TumCG↓, TumW↓,
8819- MCP,  PacT,    Pectasol‐C Modified Citrus Pectin targets Galectin‐3‐induced STAT3 activation and synergize paclitaxel cytotoxic effect on ovarian cancer spheroids
- in-vitro, Ovarian, SKOV3
Gal-3↓, ChemoSen↑, STAT3↓, Hif1a↓, Akt↓, TumCMig↓, TumCI↓, ITGA2↓, ITGA5↓, ITGA6↓, ITGB1↓, ITGB3↓, ITGB4↓,
8823- MCP,    Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model
- in-vivo, CRC, CT26
TumMeta↓, Gal-3↓, TumVol↓, Dose↝,
8822- MCP,    Modified citrus pectin inhibited bladder tumor growth through downregulation of galectin-3
- vitro+vivo, CRC, T24/HTB-9 - in-vitro, Bladder, J82
TumCCA↑, cycD1/CCND1↓, p‑cDC2↓, Casp3↑, cl‑Casp3↑, cl‑PARP↑, Gal-3↓, Akt↓, TumCG↓, Ki-67↓, Dose⇅,
8821- MCP,  Rad,    Modified Citrus Pectin as a Potential Sensitizer for Radiotherapy in Prostate Cancer
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145
Gal-3↓, TumCP↓, angioG↓, Apoptosis↑, RadioS?, BAX↓, DNArepair↓, PCNA↓, TumCI↓, TumCCA↑, ROS↑,

Showing Research Papers: 1 to 7 of 7

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

NRF2↓, 1,   ROS↓, 1,   ROS↑, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

GlucoseCon↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,   BAX↓, 1,   Casp3↑, 1,   cl‑Casp3↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 2,   STAT3↓, 1,   p‑STAT3↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNArepair↓, 1,   cl‑PARP↑, 1,   PCNA↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycD1/CCND1↓, 1,   Ki-67↓, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Ki-67↓, 1,   TumCG↓, 2,   TumCP↓, 2,  

Migration(tgid=13) ⓘ

ITGA2↓, 1,   ITGA5↓, 1,   ITGA6↓, 1,   ITGB1↓, 1,   ITGB3↓, 1,   ITGB4↓, 1,   TumCI↓, 2,   TumCMig↓, 1,   TumMeta↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 2,   Hif1a↓, 2,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

p‑cDC2↓, 1,   Gal-3↓, 7,   Imm↑, 1,   pol-M2 MC↓, 1,   NK cell↑, 1,   PSA↓, 1,   T-Cell↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,   Dose⇅, 1,   Dose↝, 2,   RadioS?, 1,  

Clinical Biomarkers(tgid=22) ⓘ

PSA↓, 1,  

Functional Outcomes(tgid=23) ⓘ

TumVol↓, 1,   TumW↓, 1,  
Total Targets: 47

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,  
Total Targets: 1

Scientific Paper Hit Count for: Gal-3, LGALS3, galectin-3
7 Modified Citrus Pectin
1 Paclitaxel/Taxol
1 Radiotherapy/Radiation
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:0  prod#:%  Target#:1893  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page